<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159289</url>
  </required_header>
  <id_info>
    <org_study_id>2002AT032B</org_study_id>
    <nct_id>NCT00159289</nct_id>
  </id_info>
  <brief_title>Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Effect of Endotoxin on Inflammatory Markers in Exhaled Breath, Sputum, Saliva and Nasal Lavage in Healthy Non-Smokers and Current Smokers Including Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate the effects of inhaled lipopolysaccharide&#xD;
      endotoxin (LPS) on bronchial and alveolar exhaled nitric oxide (NO) and NO metabolites and&#xD;
      other inflammatory markers and mediators in exhaled breath condensate, induced sputum, nasal&#xD;
      lavage and mouthwash fluid in healthy non-smokers and current smokers, including patients&#xD;
      with chronic obstructive pulmonary disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No resources available&#xD;
  </why_stopped>
  <start_date>June 2003</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sputum induced</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of LPS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLacebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inhalation of LPS</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy non-smokers: normal spirometry (forced expiratory volume in 1 second [FEV1]&#xD;
             more than or equal to 90% predicted) and normal exhaled NO (between 8 and 24 ppb; flow&#xD;
             50 ml/s)&#xD;
&#xD;
          -  0: At risk (current or ex-smokers): normal spirometry, with or without chronic&#xD;
             symptoms (cough, sputum production)&#xD;
&#xD;
          -  I-II: Mild-moderate COPD&#xD;
&#xD;
               -  FEV1 reversibility of &lt; 15% after inhaled beta2-agonists&#xD;
&#xD;
               -  FEV1/forced vital capacity (FVC) &lt; 70% predicted&#xD;
&#xD;
               -  FEV1 between greater than or equal to 50% and less than 80%&#xD;
&#xD;
               -  With or without chronic symptoms (cough, sputum production)&#xD;
&#xD;
          -  Able to comprehend and grant a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant use or pre-treatment within the last 4 weeks with oral steroids&#xD;
&#xD;
          -  Respiratory infection within 4 weeks prior to entry into the trial&#xD;
&#xD;
          -  Females who are pregnant or lactating&#xD;
&#xD;
          -  History of current or past drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergei A Kharitonov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <keyword>Mild to moderate Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>Volunteers (healthy non-smokers)</keyword>
  <keyword>Volunteers (current or ex-smokers)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

